Polysialic acid: Overcoming the hurdles of drug delivery

Therapeutic Delivery

Volumn 5, Issue 3, 2014, Pages 235-237

  Bader, Rebecca A ^a   Wardwell, Patricia R ^a  

^a Syracuse University   (United States)

Author keywords

drug delivery; nanocarriers; PEG; polysialic acid

Indexed keywords

ALDEHYDE DEHYDROGENASE; ASPARAGINASE; BLOOD CLOTTING FACTOR 8; DECYLAMINE; DICARBOXYLIC ACID; DRUG CARRIER; ERYTHROPOIETIN; HYDROCARBON; IMMUNOGLOBULIN M; INSULIN; LIPOSOME; NANOCARRIER; NERVE CELL ADHESION MOLECULE; POLYCAPROLACTONE; POLYSIALIC ACID;

BIOCOMPATIBILITY; CANCER GROWTH; CARDIOVASCULAR DISEASE; CELL INTERACTION; CIRCULATION TIME; COMPLEMENT SYSTEM; CYSTIC FIBROSIS; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; METASTASIS; NONHUMAN; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; REVIEW; RHEUMATOID ARTHRITIS;

ANIMALS; BIOCOMPATIBLE MATERIALS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; HUMANS; SIALIC ACIDS; TECHNOLOGY, PHARMACEUTICAL;

EID: 84896795649     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.13.153     Document Type: Review

References (20)

1. Fishburn CS. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J. Pharm. Sci. 97(10), 4167-4183 (2008).
2. Semple SC, Harasym TO, Clow KA, Ansell SM, Klimuk SK, Hope MJ. Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic acids. J. Pharmacol. Exp. Ther. 312(3), 1020-1026 (2005).
3. Hamad I, Hunter AC, Szebeni J, Moghimi SM. Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Mol. Immunol. 46(2), 225-232 (2008).
4. Webster R, Didier E, Harris P et al. PEGylated proteins: evaluation of their safety in the absense of definitive metabolism studies. Drug Metab. Dispos. 35(1), 9-16, (2007).
5. Gregoriadis G, Mccormack B, Wang Z, Lifely R. Polysialic acids: potential in drug delivery. FEBS Lett. 315(3), 271-276 (1993).
6. Dube DH, Bertozzi CR. Glycans in cancer and inflammation. Potential for therapeutics and diagnostics. Nat. Rev. Drug Discov. 4(6), 477-488 (2005).
7. Rutishauser U. Polysialic acid at the cell surface: biophysics in service of cell interactions and tissue plasticity. J. Cell. Biochem. 70(3), 304-312 (1998).
8. Muhlenhoff M, Eckhardt M, Gerardy-Schahn R. Polysialic acid: three-dimensional structure, biosynthesis and function. Curr. Opin. Struct. Biol. 8(5), 558-564 (1998).
9. Gregoriadis G, Fernandes A, Mccormack B, Mital M, Zhang X. Polysialic acids: potential role in therapeutic constructs. Biotechnol. Genet. Eng. Rev. 16, 203-215 (1999).
10. Gregoriadis G, Fernandes A, Mital M, Mccormack B. Polysialic acids: potential in improving the stability and pharmacokinetics of proteins and other therapeutics. Cell. Mol. Life Sci. 57(13-14), 1964-1969 (2000).
11. Fernandes AI, Gregoriadis G. The effect of polysialylation on the immunogenicity and antigenicity of asparaginase: implication in its pharmacokinetics. Int. J. Pharm. 217(1-2), 215-224 (2001).
12. Emperor design. Product pipeline PolyXen. Xenetic biosciences (2011). www.xeneticbio.com/polyxen-product-pipeline.aspx
13. Valderrama-Rincon JD, Fisher AC, Merritt JH et al. An engineered eukaryotic protein glycosylation pathway in Escherichia coli. Nat. Chem. Biol. 8(5), 434-436 (2012).
14. Greco F, Arif I, Botting R et al. Polysialic acid as a drug carrier: evaluation of a new polysialic acid-epirubicin conjugate and its comparison against established drug carriers. Polym. Chem. 4(5), 1600-1609 (2013).
15. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 53(2), 283-318 (2001).
16. Yamauchi H, Yano T, Kato T et al. Effects of sialic-acid derivative on long circulation time and tumor concentration of liposomes. Int. J. Pharm. 113(2), 141-148 (1995).
17. Bondioli L, Costantino L, Ballestrazzi A et al. PLGA nanoparticles surface decorated with the sialic acid, N-acetylneuraminic acid. Biomaterials 31(12), 3395-3403 (2010).
18. Bader RA, Silvers AL, Zhang N. Polysialic acid-based micelles for encapsulation of hydrophobic drugs. Biomacromolecules 12(2), 314-320 (2011).
19. Wilson DR, Zhang N, Silvers AL, Forstner MB, Bader RA. Synthesis and evaluation of cyclosporine A-loaded polysialic acid-polycaprolactone micelles for rheumatoid arthritis. Eur. J. Pharm. Sci. 51, 146-156 (2014).
20. Zhang N, Bader RA: US2012/0294904 A1 (2012).